Search

Displaying results 871 - 880 of 1100 in total
  1. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in ...

  2. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent in...

  3. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Azficel-T is marketed in the US as Laviv for intradermal injection.

  4. Drug

    Lutetium Lu 177-DTPA-omburtamab

    go.drugbank.com/drugs/DB31015
    Investigational

    Lutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]

  5. Drug

    Secretin human

    go.drugbank.com/drugs/DB09532
    ApprovedInvestigational

    Purified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S..

  6. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug.

  7. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_.

  8. Drug

    Glipizide

    go.drugbank.com/drugs/DB01067
    ApprovedInvestigational

    It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S.

  9. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United ...

  10. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.